HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

In the RV144 trial, vaccine-induced V1V2 IgG correlated with decreased HIV-1 risk. We investigated circulating antibody specificities in two phase 1 poxvirus prime-protein boost clinical trials conducted in South Africa: HVTN 097 (subtype B/E) and HVTN 100 (subtype C). With cross-subtype peptide mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xiaoying, Laher, Fatima, Moodie, Zoe, McMillan, Arthur S., Spreng, Rachel L., Gilbert, Peter B., Huang, Ying, Yates, Nicole L., Grunenberg, Nicole, Juliana McElrath, M., Allen, Mary, Pensiero, Michael, Mehra, Vijay L., Der Meeren, Olivier Van, Barnett, Susan W., Phogat, Sanjay, Gray, Glenda E., Bekker, Linda-Gail, Corey, Lawrence, Tomaras, Georgia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005751/
https://www.ncbi.nlm.nih.gov/pubmed/32034163
http://dx.doi.org/10.1038/s41598-020-57491-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005751/
https://www.ncbi.nlm.nih.gov/pubmed/32034163
http://dx.doi.org/10.1038/s41598-020-57491-z

Ejemplares similares